trial

Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue

NCTId NCT01794429
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 45 (actual)
Sponsored by Bjorn H. Ebdrup
Primary completion 2015-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
45 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2013-02
Primary completion
2015-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Exenatide

Sponsors

Bjorn H. EbdrupLead Sponsor

Investigators

1
Pelle L Ishøy, MDPrincipal Investigator

Sites

1 total
Glostrup Municipality, Denmark

Linked catalysts

1
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue — primary completion2015-06

Facts & assertions

4 sourced
Enrollment
45
Phase
PHASE3
Primary Completion Date
2015-06
Status
COMPLETED
relationships
The graph out of here
drug
Exenatide
drug
lead_sponsor
Bjorn H. Ebdrup
company
indication
Obesity
indication
Metabolic Syndrome x
indication
Metabolic Syndrome
indication
investigator
Pelle L Ishøy, MD
person